Risankizumab was associated with significant improvements in health-related quality of life and psoriasis symptoms compared with ustekinumab and placebo, according to the findings of a recent analysis.
In this study, the researchers analyzed data from two identical randomized trials (UltIMMa-1 and UltIMMa-2) that included 997 patients with moderate to severe plaque psoriasis. Over a 52-week period, patients were randomized 3:1:1 to receive either 150 mg of risankizumab, or 45 mg or 90 mg of ustekinumab, or placebo for 12 weeks followed by risankizumab for the trial remainder. They compared scores on the Psoriasis Symptom Scale (PSS), Dermatology Life Quality Index (DLQI), 5-level EuroQoL-5D (EQ-5D-5L), and Hospital Anxiety and Depression Scale (HADS) at baseline, week 16, and week 52.
The researchers found a significantly greater proportion of patients treated with risankizumab had no psoriasis symptoms based on the PSS compared with ustekinumab or placebo at week 16 (30% vs 15.1% vs 1%, respectively), as well as a DLQI score of 0 or 1 (66.2% vs 44.7% vs 6%). Compared with the ustekinumab and placebo groups, a significantly greater proportion of patients in the risankizumab group achieved minimally clinically important difference for DLQI (85.1% vs 35.5% vs 94.5%, respectively), EQ-5D-5L (31.5% vs 19% vs 41.7%), and HADS (anxiety: 57.1% vs 35.9% vs 69.1%; depression: 60.4% vs 37.1% vs 71.1%).
In addition, patients treated with risankizumab sustained improvements in PSS, DLQI, and EQ-5D-5L scores compared with those treated with ustekinumab.
“Risankizumab is an efficacious novel biologic treatment with meaningful improvements in symptoms, mental health, and quality of life for patients with psoriasis,” the researchers concluded.
Augustin M, Lambert J, Zema C, et al. Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials. JAMA Dermatol. Published online October 14, 2020. doi:10.1001/jamadermatol.2020.3617